Agreement Template Sample Clauses

An Agreement Template clause establishes a standardized framework for creating contracts between parties. It outlines the essential terms, conditions, and structure that will be used as a starting point for future agreements, ensuring consistency across multiple contracts. By providing a pre-approved format, this clause streamlines the drafting process and reduces the risk of omissions or inconsistencies, ultimately promoting efficiency and clarity in contractual relationships.
Agreement Template. 4 3.1 Minimum Provisions 4 3.1.1 Flow Limitations 4
View SourceView Similar (2)
Agreement Template. The City has developed a draft Inter-Jurisdictional Agreement template for use in developing, negotiating and enforcing agreements with neighboring utilities which discharge sewage into the City‘s Interceptor Sewer System (ISS). A copy of the Template is attached in Appendix A.
View SourceView Similar (2)
Agreement Template. Experience Life May 12th, 2018 - Terms amp Conditions Terms amp Conditions For members living in NSW VIC and QLD' May 9th, 2018 - This form is a sample agreement for membership to a health and or fitness facility and sets forth the rules of the club as well as contractual provisions regarding fees cancellation waiver of liability etc' MAY 11TH, 2018 - LIFE GYM L L C MEMBERSHIP AGREEMENT PAGE 1 LIFE GYM L L C MEMBERSHIP AGREEMENT FULL NAME THE FACILITY IS AN UNMANNED FITNESS CENTER AND WITH THE'
View Source
Agreement Template. Photography Contract Templates - Contractista
View Source
Agreement Template. INTERJURISDICTIONAL COOPERATIVE AGREEMENT An Agreement Between the State of Nevada Acting By and Through Its DEPARTMENT OF ______________ (NAME, ADDRESS, PHONE AND FACSIMILE NUMBER OF CONTRACTING AGENCY) And THE __________ TRIBE (NAME, ADDRESS, PHONE AND FACSIMILE NUMBER OF CONTRACTING TRIBE)
View Source
Agreement Template. For bilateral agreements with another UN Agency, this B2 template will not apply; Instead, please use the standard UN to UN Transfer Agreement.
View Source
Agreement Template. This Auto Accident Settlement Agreement and Release (“Agreement”) is entered into by and between , herein referred to as the “Releasor,” and , herein referred to as the “Releasee.”
View Source
Agreement Template. A California residential purchase and sale agreement is a contract between an individual/entity selling a property and the individual/entity intent on purchasing said property. The parties, buyer and seller, will settle the terms of this agreement to arrive at a mutually beneficial arrangement. A price will be set by the seller (and perhaps negotiated by the buyer) and a closing date for the ...
View Source
Agreement Template. It has a similar structure to the Agreement, however, with an additional section called the ìAgreement Creation Constraintî. This constraint section states valid and acceptable values. Figure 2.4 shows the generally accepted structure of an SLA taken from the WS- Agreement specification. WS-Agreement is a specification that has been defined and accepted by the Grid Resource Allocation Agreement Protocol Working Group (▇▇▇▇▇-WG). The ▇▇▇▇▇-WG (2003), produces a set of specifications and supporting documents, which describe methods and means to establish SLAs between different entities in a distributed environment.
View Source

Related to Agreement Template

  • Agreement Terms The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $230,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Client Agreement We are not required to enter into a written agreement complying with the Code relating to the services that are to be provided to you.

  • Transition Agreement 12.8.1 In the event of termination of this Agreement, whether in its entirety or with respect to the Terminated Territory, Ablynx and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Ablynx will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Ablynx as reasonably necessary for Ablynx to exercise its licenses pursuant to Sections 12.6 and 12.7 with respect to the Licensed Products after termination of this Agreement (in its entirety or with respect to the Terminated Territory, as applicable) as and to the extent set forth in this Article 12. For purposes of clarity, AbbVie shall not be required to Manufacture or have Manufactured the Licensed Products by or on behalf of Ablynx as part of the Transition Agreement. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3 or by Ablynx in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie and in its name applicable to the Licensed Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) unless expressly prohibited by any Regulatory Authority, transfer control to Ablynx of all Clinical Studies being Conducted by AbbVie as of the effective date of termination and continue to Conduct such Clinical Studies, […***…], for up to […***…] to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Ablynx shall not have any obligation to continue any Clinical Study unless required by Applicable Law, in which case Ablynx, if it wishes to terminate such Clinical Study, shall continue such Clinical Study […***…] until such time that Applicable Law allows such trial to be terminated (with Ablynx taking all reasonable steps to promptly terminate such Clinical Study and minimize all costs and expenses), and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, […***…]; (iv) assign (or cause its Affiliates to assign) to Ablynx all agreements with any Third Party with respect to the conduct of pre-clinical Development activities, Manufacturing or Clinical Studies for the Licensed Products, including agreements with contract research organizations, contract manufacturing organizations, clinical sites, and investigators, unless, with respect to any such agreement, such agreement (a) expressly prohibits such assignment, in which case AbbVie shall cooperate with Ablynx in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (b) covers Clinical Studies for Combination Products in which any active ingredient that is not a Licensed Compound is covered by Patents Controlled by AbbVie or any of its Affiliates or covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Licensed Products, in which case AbbVie shall, […***…], cooperate with Ablynx in all reasonable respects to facilitate the execution of a new agreement between Ablynx and the applicable Third Party; and (v) transfer to Ablynx all existing clinical supplies of the Licensed Compound or Licensed Product in the possession of AbbVie at the time of termination, which shall be […***…]. CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. In the event this Agreement is partially terminated or terminated in its entirety by Ablynx pursuant Section 12.2.1, then any actions or activities set forth in the Transition Agreement shall be […***…]. 12.8.3 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3.2 or with respect to a Terminated Territory by Ablynx pursuant to Section 12.2.2 (but not in the case of any termination of this Agreement in its entirety), AbbVie shall in a reasonable amount of time following Ablynx’s request: (i) where permitted by Applicable Law, transfer to Ablynx all of its right, title, and interest in all Regulatory Approvals owned by AbbVie and then in its name that is solely applicable to the Terminated Territory and to the Licensed Products that are the subject of an exclusive license grant in Section 12.7.2, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Licensed Products in the Territory, Develop Licensed Products in support of such Commercialization, or Manufacture Licensed Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Ablynx a right of reference to all Regulatory Documentation then owned by AbbVie and in AbbVie’s name that are not transferred to Ablynx pursuant to clause (i) above that are necessary or reasonably useful for Ablynx, any of its Affiliates or sublicensees to Develop or Commercialize any Licensed Products that are the subject of the license grant in Section 12.7.2, as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such Terminated Territory.

  • Agreement Exceptions/Deviations Explanation If the proposing Vendor desires to deviate form the Vendor Agreement language, all such deviations must be listed on this attribute, with complete and detailed conditions and information included. TIPS will consider any deviations in its proposal award decisions, and TIPS reserves the right to accept or reject any proposal based upon any deviations indicated below. In the absence of any deviation entry on this attribute, the proposer assures TIPS of their full compliance with the Vendor Agreement.